Form 4 for NVCR NovoCure Ltd
Accepted 2024-11-06 00:00:00 ET · period of report 2024-11-02 · accession 0001562180-24-007567 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-06 | 2024-11-04 | NVCR | Paravasthu Mukund | COO | A - Grant | $0.00 | +30.1K | 33.6K | +871% | $0 |
| D | 2024-11-06 | 2024-11-02 | NVCR | Paravasthu Mukund | COO | S - Sale | $16.69 | -44 | 3,459 | -1% | -$734.36 |
| D | 2024-11-06 | 2024-11-04 | NVCR | Paravasthu Mukund | COO | A - Grant | $16.59 | +45.6K | 45.6K | New | +$756.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-11-04 | A | A | 30,138 | $0.00 | 33,597 | D | — | — | (F2) Represents restricted share units that are scheduled to vest in equal parts on November 4, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. |
| 2 | Common | Ordinary Shares | 2024-11-02 | S | D | 44 | $16.69 | 3,459 | D | — | — | (F1) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-11-04 | A | A | 45,620 | $16.59 | 45,620 | D | $16.59 · — to 2034-11-03 | 45,620 Ordinary Shares | (F3) Options to buy 45,620 ordinary shares will vest in equal installments on each of November 4, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. |